Study on Livmarli for Alagille Syndrome (LEAP)
This study looks at how safe Livmarli is over a long time for people with Alagille Syndrome (ALGS). ALGS is a rare disease that affects many body systems and often causes jaundice, which is yellowing of the skin and eyes, in babies. Livmarli is a medicine that helps with itching caused by a problem called cholestasis, where bile doesn't flow properly in the liver. It works by lowering bile acid levels in the body.
Key Points:
- The study is observational, meaning doctors will watch and record what happens over time, without changing treatments.
- Participants need to have a confirmed diagnosis of ALGS and be taking Livmarli.
- People who have used Livmarli in other studies or programs, or who have received certain liver treatments, cannot join.
If you're eligible, you might need to visit the study site for check-ups. This study does not mention compensation details, so it's important to ask about any costs or benefits. Always talk to your doctor to see if this study is right for you.
How understandable was the trial content above?
Hard to understand
Easy to understand